[go: up one dir, main page]

WO2011156331A3 - Human neural progenitor derived dopaminergic progenitors and neurons - Google Patents

Human neural progenitor derived dopaminergic progenitors and neurons Download PDF

Info

Publication number
WO2011156331A3
WO2011156331A3 PCT/US2011/039389 US2011039389W WO2011156331A3 WO 2011156331 A3 WO2011156331 A3 WO 2011156331A3 US 2011039389 W US2011039389 W US 2011039389W WO 2011156331 A3 WO2011156331 A3 WO 2011156331A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurons
human neural
neural progenitor
dopaminergic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/039389
Other languages
French (fr)
Other versions
WO2011156331A2 (en
WO2011156331A9 (en
Inventor
Steven L. Stice
Amber Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia, University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia
Publication of WO2011156331A2 publication Critical patent/WO2011156331A2/en
Publication of WO2011156331A3 publication Critical patent/WO2011156331A3/en
Anticipated expiration legal-status Critical
Publication of WO2011156331A9 publication Critical patent/WO2011156331A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/32—Polylysine, polyornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for producing mature dopaminergic neurons from human neural progenitor cells and/or from dopaminergic progenitor cells. The invention provides these cells from human embryonic stem cell (hESC) derived human neural progenitor (hNP) cells or from dopaminergic progenitor cells as otherwise described herein, A dopaminergic progenitor cell, which can lead to the differentiation/production of mature dopaminergic in high yield, is an additional aspect of the present invention.
PCT/US2011/039389 2010-06-08 2011-06-07 Human neural progenitor derived dopaminergic progenitors and neurons Ceased WO2011156331A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35258510P 2010-06-08 2010-06-08
US61/352,585 2010-06-08

Publications (3)

Publication Number Publication Date
WO2011156331A2 WO2011156331A2 (en) 2011-12-15
WO2011156331A3 true WO2011156331A3 (en) 2012-05-10
WO2011156331A9 WO2011156331A9 (en) 2013-03-07

Family

ID=45098611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039389 Ceased WO2011156331A2 (en) 2010-06-08 2011-06-07 Human neural progenitor derived dopaminergic progenitors and neurons

Country Status (1)

Country Link
WO (1) WO2011156331A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2991560B1 (en) 2013-04-30 2020-07-29 Cedars-Sinai Medical Center Stabilization apparatuses for medical procedures
WO2016069936A1 (en) * 2014-10-29 2016-05-06 Cedars-Sinai Medical Center Apparatuses, systems and methods for controlled delivery of therapeutics and related substances
CN107438669B (en) * 2015-04-09 2022-09-27 拜奥拉米那公司 Methods and compositions for the production of stem cell-derived dopaminergic cells for the treatment of neurodegenerative diseases
US10081791B2 (en) 2015-05-07 2018-09-25 William J. Freed Modeling connections between dopaminergic neurons and the cerebral cortex
CN117448270B (en) * 2023-12-22 2024-07-26 上海元戊医学技术有限公司 A method for efficiently inducing pluripotent stem cells to differentiate into midbrain dopaminergic neural precursor cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MORIZANE ET AL.: "Generation of graftable dopaminergic neuron progenitors from mouse ES cells by a combination of coculture and neurosphere Methods", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 83, 2006, pages 1015 - 1027 *
POTTER ET AL.: "Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons", CELL AND TISSUE RESEARCH, vol. 296, 1999, pages 235 - 246 *
PRAKASH ET AL.: "Development of dopaminergic neurons in the mammalian brain", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 63, 2006, pages 187 - 206 *
WANG ET AL.: "Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, vol. 22, 2004, pages 175 - 183 *
YOUNG ET AL.: "Glial cell line-derived neurotrophic factor enhances in vitro differentiation of mid-/hindbrain neural progenitor cells to dopaminergic-like neurons", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 88, 20 September 2010 (2010-09-20), pages 3222 - 3232 *

Also Published As

Publication number Publication date
WO2011156331A2 (en) 2011-12-15
WO2011156331A9 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2011011302A3 (en) Differentiation of human embryonic stem cells
WO2012135621A3 (en) Priming of pluripotent stem cells for neural differentiation
WO2013124816A8 (en) Generation of neural stem cells and motor neurons
MX2013004353A (en) Recombinant n-propanol and isopropanol production.
WO2011134919A3 (en) Cho cells cultivation process 0
WO2012030539A3 (en) Differentiation of human embryonic stem cells
EP3546568A3 (en) Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins ln-511, ln-521 and ln-221
WO2012171030A3 (en) Method and apparatus for antibody production and purification
WO2014011881A3 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2012074818A3 (en) Compositions and methods for 3-hydroxypropionic acid production
NZ628964A (en) Supercritical hydrolysis of biomass
WO2013000717A3 (en) Dermatologically effective yeast extract
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
WO2012030538A3 (en) Differentiation of human embryonic stem cells
WO2011156331A3 (en) Human neural progenitor derived dopaminergic progenitors and neurons
WO2011156794A3 (en) Synthetic pathways for biofuel synthesis
MY184796A (en) Method for manufacturing ciliary marginal zone-like structure
WO2011129462A3 (en) A YEAST EXTRACT CONTAINING γ-Glu-X OR γ-Glu-X-Gly AND A METHOD FOR PRODUCING THE SAME
WO2014052920A3 (en) Methods of producing acetoin and 2,3-butanediol using photosynthetic microorganisms
MY184072A (en) Increasing virus like particle yield in plants
WO2012142094A3 (en) Compositions and methods for increased ethanol production from biomass
EP3666900A3 (en) Cell-based production of nonulosonates
WO2011159050A3 (en) Method for differentiating human neural progenitor cells into dopaminergic neurons, and medium for differentiation thereof
SG194703A1 (en) Multistage cellulose hydrolysis and quench with or without acid
WO2012031166A3 (en) Expression of steady state metabolic pathways

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11792994

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11792994

Country of ref document: EP

Kind code of ref document: A2